Avricore Health Inc. (TSE:AVCR)
:AVCR
Top Page
Avricore Health
(AVCR)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.06
▲(28.00% Upside)
Action:ReiteratedDate:01/16/26
The score is held down primarily by weak financial performance, led by a sharp TTM revenue decline, deep losses, and a return to free-cash-flow burn. Technicals provide some support with the stock trading above major moving averages and a positive MACD, but overbought signals (high RSI/Stoch) add risk. Valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Pharmacy-based POC testing platform
Avricore's business model sells both services and platform capabilities to community pharmacies, creating multiple revenue levers (per-test, platform fees, program contracts). That diversified service+software model supports recurring program revenue and scalable site expansion if partnerships grow.
Negative Factors
Sharp TTM revenue decline
A near-40% TTM revenue drop and deep negative margins materially reduce the company's ability to realize operating leverage from its decent gross margin. Sustained declines erode scale, compress cash generation, and make it harder to fund platform development or expand pharmacy programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Pharmacy-based POC testing platform
Avricore's business model sells both services and platform capabilities to community pharmacies, creating multiple revenue levers (per-test, platform fees, program contracts). That diversified service+software model supports recurring program revenue and scalable site expansion if partnerships grow.
Read all positive factors
Avricore Health (AVCR) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$6.58M
Dividend YieldN/A
Average Volume (3M)51.37K
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue Growth-59.28%
EPS Growth-1563.64%
CountryCA
Employees26
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding101,289,665
10 Day Avg. Volume29,762
30 Day Avg. Volume51,367
Financial Highlights & Ratios
PEG Ratio1.92
Price to Book (P/B)2.80
Price to Sales (P/S)1.15
P/FCF Ratio6.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Avricore Health Business Overview & Revenue Model
Company Description
Avricore Health Inc. engages in the health data and point-of-care technologies business in Canada. It provides HealthTab, a lab-accurate point of care testing platform for pharmacy. The company has strategic partnerships with Shoppers Drug Marts a...
How the Company Makes Money
Avricore Health generates revenue through the sale and deployment of its HealthTab platform in partnership with pharmacies and healthcare providers. The company earns money by charging fees for each test conducted on its platform and through subsc...
Avricore Health Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.92M | 4.79M | 3.49M | 1.77M | 122.81K | 33.03K |
| Gross Profit | 834.20K | 1.88M | 1.20M | 456.79K | 30.52K | 17.48K |
| EBITDA | -590.41K | -208.44K | -275.14K | -629.76K | -1.64M | -930.40K |
| Net Income | -1.63M | -668.98K | -701.22K | -818.23K | -1.71M | -1.17M |
Balance Sheet | ||||||
| Total Assets | 1.33M | 2.30M | 2.54M | 2.57M | 2.28M | 440.09K |
| Cash, Cash Equivalents and Short-Term Investments | 541.75K | 1.14M | 286.57K | 630.53K | 2.01M | 302.71K |
| Total Debt | 0.00 | 0.00 | 40.00K | 40.00K | 40.00K | 1.00M |
| Total Liabilities | 35.88K | 330.82K | 529.22K | 604.89K | 84.48K | 1.15M |
| Stockholders Equity | 1.29M | 1.97M | 2.01M | 1.96M | 2.20M | -714.04K |
Cash Flow | ||||||
| Free Cash Flow | -263.03K | 799.27K | -386.46K | -1.64M | -1.37M | -1.22M |
| Operating Cash Flow | -146.71K | 1.00M | 660.40K | -437.83K | -1.23M | -1.22M |
| Investing Cash Flow | -119.03K | -205.35K | -1.05M | -1.21M | -140.36K | 0.00 |
| Financing Cash Flow | 17.50K | 56.60K | 42.50K | 253.88K | 3.08M | 1.51M |
Avricore Health Technical Analysis
Positive
0.05
Price Trends
0.07
Negative
0.06
Positive
0.07
Positive
Market Momentum
>-0.01
Positive
48.81
Neutral
10.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AVCR, the sentiment is Positive. The current price of 0.05 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.81 is Neutral, neither overbought nor oversold. The STOCH value of 10.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AVCR.
Avricore Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$63.05M | -32.47 | ― | ― | -21.89% | 26.36% | |
47 Neutral | C$6.58M | -4.67 | -95.29% | ― | -59.28% | -1563.64% | |
47 Neutral | C$6.03M | -2.38 | -9999.00% | ― | ― | 19.05% | |
42 Neutral | C$6.67M | -4.68 | ― | ― | ― | 81.01% |
* Healthcare Sector Average
TSE:AVCR
Avricore Health
0.07
0.02
44.44%
TSE:BUX
BioMark Diagnostics
0.60
0.35
135.29%
TSE:TELO
Telo Genomics Corp
0.06
-0.04
-40.00%
TSE:SZLS.H
StageZero Life Sciences Ltd
0.04
0.00
0.00%
TSE:NARA
PanGenomic Health, Inc. Class A
0.48
0.27
126.19%
Avricore Health Corporate Events
Business Operations and StrategyProduct-Related Announcements
Avricore to Expand HealthTab Testing Network Across North East London Pharmacies
Positive
Jan 14, 2026
Avricore Health is expanding its HealthTab point-of-care testing platform across North East London, rolling out to an additional 70 community pharmacy sites following the success of its NHS-linked cardiovascular programmes with Barts Health NHS Tr...
Business Operations and StrategyProduct-Related Announcements
Avricore Health’s HealthTab Expands Role in NHS Cardiovascular Care Pilot
Positive
Nov 28, 2025
Avricore Health’s HealthTab platform is being utilized in a new pilot program by Barts Health NHS Trust to deliver cholesterol-lowering injections through community pharmacies in the UK. This initiative marks a significant expansion of Healt...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.